Overview
MIRM market data
Price History
MIRM price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.47 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.60 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -139.2% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $63.23 – $130.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $6.4B · P/B 12.97 · P/S 10.31.
Company News
TD Cowen Maintains Buy on Mirum Pharmaceuticals, Lowers Price Target to $140Benzinga · Aug 6, 2026, 7:52 PM
RBC Capital Maintains Outperform on Mirum Pharmaceuticals, Lowers Price Target to $135Benzinga · Aug 6, 2026, 5:40 PM
Citizens Maintains Market Outperform on Mirum Pharmaceuticals, Lowers Price Target to $137Benzinga · Aug 6, 2026, 1:01 PM
Mirum Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q2 adjusted EPS results. Also, HC Wainwright & Co lowered its price target on the stock from $185 to $140.Benzinga · Aug 6, 2026, 11:50 AM
HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Lowers Price Target to $140Benzinga · Aug 6, 2026, 11:04 AM
CORRECTION: Mirum Pharmaceuticals Q2 Adj. EPS $(0.80) Misses $(0.68) Estimate, Sales $176.243M Beat $166.122M EstimateBenzinga · Aug 5, 2026, 10:11 PM
Mirum Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q2 adjusted EPS results.Benzinga · Aug 5, 2026, 8:46 PM
Mirum Pharmaceuticals Raises FY2026 Sales Guidance from $660.000M-$680.000M to $680.000M-$700.000M vs $675.249M EstBenzinga · Aug 5, 2026, 8:04 PM
Mirum Pharmaceuticals Q2 Adj. EPS $(1.06) Misses $(0.68) Estimate, Sales $176.200M Beat $166.122M EstimateBenzinga · Aug 5, 2026, 8:03 PM
Arcutis Expands Board of Directors with Appointment of Chris PeetzGlobenewswire Inc · Jul 16, 2026, 1:15 PM